GlassScriptPhysician profile
Barzan Mohedin
NPI 1639235096
$13,870.09
in general payments reported to CMS, 2019-2025
50 companies · $2,196 in 2025
The $2,196 reported for 2025 was more than what 88% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,969 · 2020: $773 · 2021: $2,342 · 2022: $2,356 · 2023: $2,272 · 2024: $1,964 · 2025: $2,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,420 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,420.11 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,607.41 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,374.68 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $1,301.46 | 2019-2025 | Tezspire, Airsupra, Andexxa |
| Novo Nordisk INC | $776.77 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $770.10 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $683.68 | 2019-2025 | Zerbaxa, Dificid, Winrevair |
| Lilly USA, LLC | $668.02 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Chiesi USA, INC. | $608.23 | 2022-2025 | Cleviprex |
| Pfizer INC. | $490.67 | 2019-2025 | |
| La Jolla Pharmaceutical Company | $379.51 | 2021-2023 | Giapreza |
| Abbott Laboratories | $288.10 | 2023-2025 | Aveir, Navitor, Cardiomems |
| Abiomed | $276.77 | 2023-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $267.44 | 2021-2022 | |
| Abbvie INC. | $266.75 | 2021-2025 | |
| Daiichi Sankyo INC. | $262.58 | 2020-2023 | Injectafer |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barzan Mohedin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.